On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community.
SARS-CoV-2
age
children
high schools
primary schools
secondary schools
seroprevalence
susceptibility
young adults
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
13 02 2021
13 02 2021
Historique:
received:
31
07
2020
accepted:
28
10
2020
pubmed:
30
10
2020
medline:
3
3
2021
entrez:
29
10
2020
Statut:
ppublish
Résumé
There is limited information on the effect of age on the transmission of SARS-CoV-2 infection in different settings. We reviewed published studies/data on detection of SARS-CoV-2 infection in contacts of COVID-19 cases, serological studies, and studies of infections in schools. Compared to younger/middle-aged adults, susceptibility to infection for children younger than 10 years is estimated to be significantly lower, while estimated susceptibility to infection in adults older than 60 years is higher. Serological studies suggest that younger adults (particularly those younger than 35 years) often have high cumulative incidence of SARS-CoV-2 infection in the community. There is some evidence that given limited control measures, SARS-CoV-2 may spread robustly in secondary/high schools, and to a lesser degree in primary schools, with class size possibly affecting that spread. There is also evidence of more limited spread in schools when some mitigation measures are implemented. Several potential biases that may affect these studies are discussed. Mitigation measures should be implemented when opening schools, particularly secondary/high schools. Efforts should be undertaken to diminish mixing in younger adults, particularly individuals aged 18-35 years, to mitigate the spread of the epidemic in the community.
Sections du résumé
BACKGROUND
There is limited information on the effect of age on the transmission of SARS-CoV-2 infection in different settings.
METHODS
We reviewed published studies/data on detection of SARS-CoV-2 infection in contacts of COVID-19 cases, serological studies, and studies of infections in schools.
RESULTS
Compared to younger/middle-aged adults, susceptibility to infection for children younger than 10 years is estimated to be significantly lower, while estimated susceptibility to infection in adults older than 60 years is higher. Serological studies suggest that younger adults (particularly those younger than 35 years) often have high cumulative incidence of SARS-CoV-2 infection in the community. There is some evidence that given limited control measures, SARS-CoV-2 may spread robustly in secondary/high schools, and to a lesser degree in primary schools, with class size possibly affecting that spread. There is also evidence of more limited spread in schools when some mitigation measures are implemented. Several potential biases that may affect these studies are discussed.
CONCLUSIONS
Mitigation measures should be implemented when opening schools, particularly secondary/high schools. Efforts should be undertaken to diminish mixing in younger adults, particularly individuals aged 18-35 years, to mitigate the spread of the epidemic in the community.
Identifiants
pubmed: 33119738
pii: 5943164
doi: 10.1093/infdis/jiaa691
pmc: PMC7665686
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
362-369Subventions
Organisme : NCI NIH HHS
ID : U01 CA261277
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM088558
Pays : United States
Commentaires et corrections
Type : UpdateOf
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Geroscience. 2020 Aug;42(4):1063-1074
pubmed: 32677025
Clin Infect Dis. 2020 Nov 19;71(16):2099-2108
pubmed: 32392331
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720942695
pubmed: 32674696
Science. 2020 Nov 6;370(6517):691-697
pubmed: 33154136
J Clin Med. 2020 Aug 27;9(9):
pubmed: 32867328
Science. 2021 Jan 1;371(6524):79-82
pubmed: 33177105
Ann Epidemiol. 2020 Aug;48:23-29.e4
pubmed: 32648546
Lancet Child Adolesc Health. 2020 Nov;4(11):807-816
pubmed: 32758454
Clin Infect Dis. 2020 Nov 5;71(8):1953-1959
pubmed: 32382743
Nat Commun. 2021 Mar 2;12(1):1383
pubmed: 33654063
Emerg Infect Dis. 2020 Oct;26(10):2465-2468
pubmed: 32673193
J Clin Med. 2020 Nov 05;9(11):
pubmed: 33167563
Lancet Infect Dis. 2020 Oct;20(10):1141-1150
pubmed: 32562601
J Infect Dis. 2020 Nov 9;222(11):1772-1775
pubmed: 32856712
Euro Surveill. 2020 Sep;25(38):
pubmed: 32975186
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
JAMA. 2020 Jun 16;323(23):2425-2427
pubmed: 32421144
Clin Infect Dis. 2020 Nov 5;71(8):1943-1946
pubmed: 32301964
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Clin Infect Dis. 2021 Jul 15;73(2):e458-e465
pubmed: 32649743
J Med Virol. 2021 Mar;93(3):1414-1420
pubmed: 32767703
Pediatr Pulmonol. 2021 Jun;56(6):1374-1377
pubmed: 33470561
JAMA Intern Med. 2020 Jul 21;:
pubmed: 32692365
Clin Infect Dis. 2021 Oct 5;73(7):e1841-e1849
pubmed: 32719874
Euro Surveill. 2020 Sep;25(36):
pubmed: 32914746
Nat Commun. 2021 Mar 9;12(1):1533
pubmed: 33750783
Science. 2020 Jun 26;368(6498):1481-1486
pubmed: 32350060
Euro Surveill. 2020 Jul;25(29):
pubmed: 32720636
Ann Intern Med. 2020 Dec 1;173(11):879-887
pubmed: 32790510
Nat Commun. 2020 Nov 17;11(1):5829
pubmed: 33203887
Rev Saude Publica. 2020;54:69
pubmed: 32638883
PLoS Comput Biol. 2021 Feb 11;17(2):e1008559
pubmed: 33571188
Lancet Glob Health. 2020 Nov;8(11):e1390-e1398
pubmed: 32979314
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
MMWR Morb Mortal Wkly Rep. 2020 Jun 12;69(23):714-721
pubmed: 32525850
Clin Microbiol Infect. 2020 Jul;26(7):842-847
pubmed: 32344166
Arch Dis Child. 2021 Jul;106(7):709-711
pubmed: 32769089